Journal Issue Information

| سال:0 | دوره: | شماره:

Archive

Year

Volume(Issue)

Issues

مرکز اطلاعات علمی SID1
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
Writer: 

ALAVIAN S.M.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    253
  • End Page: 

    254
Measures: 
  • Citations: 

    0
  • Views: 

    15336
  • Downloads: 

    10568
Keywords: 
Abstract: 

Michael Roggendorf was born on May 9, 1946, in Munich in the Federal Republic of Germany. Professor Roggendorf studied medicine at the University of Bonn from 1966 to 1974, and also studied at the Max von Pettenkofer Institute for Medical Microbiology and Hygiene at the University of Munich, where he also served as Assistant Professor and Head of the Diagnostic Laboratory of Viral Diseases and Hepatitis Research for six years between 1985 and 1991.

Yearly Impact:  

View 15336

Download 10568 Citation 0 Refrence 0
Writer: 

AGARWAL S.K.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    255
  • End Page: 

    257
Measures: 
  • Citations: 

    0
  • Views: 

    19864
  • Downloads: 

    14804
Keywords: 
Abstract: 

Hepatitis B virus (HBV) infection in patients with end-stage renal disease (ESRD) on renal replacement therapy—hemodialysis and/or renal transplantation—usually has an unfavorable course with a tendency towards chronicity leading to increased morbidity and mortality (1).

Yearly Impact:  

View 19864

Download 14804 Citation 0 Refrence 0
Writer: 

YAN X.B. | CHEN Z. | BRECHOT CH.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    257
  • End Page: 

    284
Measures: 
  • Citations: 

    0
  • Views: 

    14936
  • Downloads: 

    26601
Keywords: 
Abstract: 

Background and Aims: Because hepatitis C virus (HCV) core protein (Core), protein kinase R (PKR), and signal transducer and activator of transcription 3 (STAT3) all play relevant roles in the pathogenesis of HCV, persistent infection and hepatocellular carcinoma (HCC) and PKR may interact with HCV Core. In this study, we further investigate the associations among HCV Core, PKR, and STAT3 and the mechanisms involved in these interactions. Materials and Methods: Expression levels of HCV Core, PKR, eukaryotic initiation factor 2 (eIF-2a), phosphorylated eIF-2a (p-eIF-2a), STAT3, and phosphorylated-STAT3 (p-STAT3) were compared between Huh-7 and replicon cell-Huh-7 cells harboring the full length of genotype 1b HCV genomes. Co-immunoprecipitation and glutathione S-transferase (GST) pull-down assay were conducted for HCV Core, PKR, and STAT3. Results: HCV may have induced the expression of STAT3 and the activity of PKR (p-eIF-2a). HCV Core, STAT3, and PKR appear to have interacted with one another. The N-terminal 1-126 amino acid (aa) of HCV Core contributed to an interaction between HCV Core and STAT3, and only full-length PKR bound to STAT3 and p-STAT3. Conclusions: These findings suggest that HCV Core, PKR, and STAT3 can interact with each other. Specifically, HCV Core may play its role through both PKR and STAT3. Alternatively, HCV Core’s binding to and activation of STAT3 might be due to the interaction between HCV Core and PKR. The distinct interactions among these three molecules are important and may reveal a new molecular mechanism in the pathogenesis of HCV-persistent infection and HCV-related HCC.

Yearly Impact:  

View 14936

Download 26601 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    258
  • End Page: 

    269
Measures: 
  • Citations: 

    352
  • Views: 

    17044
  • Downloads: 

    20942
Keywords: 
Abstract: 

Hepatitis C virus infection is an emerging disease and a public health problem in the world. There are accumulating data regarding extra hepatic manifestation of HCV, such as rheumatologic manifestations, endocrine, hematologic, dermatologic, renal, neurologic, and systemic manifestations. The therapy of them needs more attention to some exacerbations of extra hepatic manifestation and in some situation it needs different approaches. In this review we tried to provide latest evidence for extra hepatic manifestation and management of them.

Yearly Impact:  

View 17044

Download 20942 Citation 352 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    270
  • End Page: 

    274
Measures: 
  • Citations: 

    0
  • Views: 

    17691
  • Downloads: 

    20482
Keywords: 
Abstract: 

Background and Aims: Hepatocellular carcinoma (HCC) is a well-known consequence of chronic liver disease (CLD). The aim of this study was to extract the HCC incidence rate in the province of Kerman, located in southern part of Iran, and compare the data with other parts of the country.Materials and Methods: All medical records related to HCC were collected through hospitals or outpatient services in public or private centers. The records of all oncology, radiotherapy, and pathology centers in Kerman province were actively searched between 1999 and 2006. The annual incidence of HCC around the country was calculated, using the national cancer registry database provided by the Health Ministry of IR Iran from 2005 to 2006. Using Stata version 8, the crude and age-sex-standardized annual incidence rates were computed.Results: The crude annual incidence rates of HCC per 100,000 persons in Kerman and Iran were 0.522 (95% CI = 0.238-0.88) and 0.199 (95% CI = 0.167-0.234), respectively. When adjusting for age and sex, the annual incidence rates of HCC in Kerman and Iran were 0.7 (95% CI = 0.4-1.1) and 0.2 (95% CI = 0.2-0.3) per 100,000 persons, respectively (P<0.01). The mean age of patients in Kerman was around 5.5 years younger than other parts of Iran (56.17 ± 18.32 years versus 61.68 ±14.62 years; P=0.004).Conclusions: In general, the incidence of HCC is not very high in Iran; however, the higher incidence of HCC in Kerman and also the lower age of onset mandates further research to detect HCC’s risk factors in this part of country.

Yearly Impact:  

View 17691

Download 20482 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    285
  • End Page: 

    288
Measures: 
  • Citations: 

    0
  • Views: 

    16285
  • Downloads: 

    22186
Keywords: 
Abstract: 

Background and Aims: An impaired lipid metabolism is often observed in patients with chronic liver diseases. To determine lipid profile in patients with cirrhosis and to asses if it relates to the severity of the cirrhosis. Materials and Methods: In an analytical cross-sectional study, 50 patients with cirrhosis (case) and 50 age- and sex-matched healthy normolipidemic patients (comparison) were studied. A questionnaire including personal characteristics, etiology of cirrhosis, pathologic criteria of CHILD and MELD and lipid profile (total, LDL, and HDL cholesterol and triglyceride) was completed for each patient. Results: In patients with cirrhosis, there was a significant decrease in serum triglyceride, total, LDL and HDL cholesterol levels compared to the comparison group (mean of 82 vs 187, 138 vs 184, 80 vs 137, and 40 vs 44 mg/dL, respectively; all p<0.05). Comparison of lipid profile with pathologic progression of cirrhosis revealed that except for serum triglyceride level, serum lipid levels diminishe linearly with progression of liver damage. Conclusions: Serum total, LDL and HDL cholesterol level in patients with cirrhosis is inversely correlate with severity of cirrhosis.

Yearly Impact:  

View 16285

Download 22186 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    289
  • End Page: 

    293
Measures: 
  • Citations: 

    0
  • Views: 

    16477
  • Downloads: 

    10437
Keywords: 
Abstract: 

Background and Aims: We aimed to evaluate the effectiveness of nucleoside analogues such as Lamivudine, Adefovir, Entacavir, and Tenofovir in patients with chronic hepatitis B who failed to respond to interferon therapy and relapsed. Materials and Methods: We followed a total of 73 patients with hepatitis B in the hepatitis outpatient clinic in our hospital. The patients subsequently received nucleoside analogues therapy and their treatment data were evaluated retrospectively. The biochemical and virological response rates were evaluated at 3 and 12 months, and we compared these results with the results of treatment-naive patients.Results: There were 29 (39.7%) HbeAg-positive and 44 (60.3%) HbeAg-negative patients, and their mean age was 35.8 (±13.4) years. Of these patients, 33, 18, 13 and 9 received Entacavir, Tenofovir, Lamivudine, and Adefovir treatment, respectively. In HbeAg-negative patients, at 3 months the biochemical and virological response (early response) rates were observed to be 91% and 98%), and at 12 months the two rates were 93% and 73%, respectively. In HbeAg-positive patients, the biochemical and virological response rates at 3 months were 83% and 97%, and the rates at 12 months were 90% and 48%, respectively. Conclusions: In CHB therapy with treatment-resistent patients, nucleoside analogues may be preferable. There are disadvantages to nucleoside analogues, such as a risk of developing resistance during therapy, reduced HBeAg seroconversion compared to interferons, and the therapy’s ambiguous duration. In our study, in HbeAg-negative patients who received nucleoside analogues, a lower biochemical response rate was detected in patients with 1 year of Lamivudine therapy compared to other therapies. For HbeAg-positive patients, the virological response rate was higher in 1 year of Tenofovir therapy than with other therapies.

Yearly Impact:  

View 16477

Download 10437 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    294
  • End Page: 

    297
Measures: 
  • Citations: 

    0
  • Views: 

    15969
  • Downloads: 

    13893
Abstract: 

Background and Aims: To investigate the prevalence and pattern of PC and BCP mutations and their clinical significance in patients with genotype D chronic hepatitis B infection in the Fars province of southern Iran.Materials and Methods: From January 2007 to March 2008, we evaluated 44 patients with chronic hepatitis B infection who were referred to our hepatology clinics affiliated with the Shiraz University of Medical Science. All Patients were HBeAg Negative and HBeAb positive. Basal core promoter and precore mutations in these patients were evaluated with clinical phenotype and laboratory tests. Results: The mean age of the patients was 37.21 ± 10.54 years. Twenty-seven patients (61.4%) had no mutations, whereas 17 patients (38.6%) had mutations in the precore or basal core promoter regions or both. The mean serum ALT level in mutation-free patients was 59.74 ± 55.86 IUL, whereas patients with PC and BCP mutations had a mean serum ALT level of 71.35 ± 59.49 IUL. The mean serum AST level in patients with mutations was higher than for patients without mutations (59.53 ± 41.35 IUL vs. 40.65 ± 25.21 IUL, respectively). There was no statistically significant difference between the mutation and mutation-free groups in terms of age, sex, and liver enzyme levels (P > 0.05). Fourteen of the 44 patients (31.8%) had mutations in the precore region (G 1896A). 17 patients (38.6%) had mutations in basal core promoter region. Conclusion: This study revealed a high prevalence of precore and basal core promoter mutations in southern Iran. Although no statistically significant difference was noted in liver enzymes, patients with mutations had higher liver enzymes in comparison with mutation-free patients.

Yearly Impact:  

View 15969

Download 13893 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    298
  • End Page: 

    301
Measures: 
  • Citations: 

    0
  • Views: 

    21495
  • Downloads: 

    29323
Abstract: 

Background and Aims: Currently, vaccination is the most effective protective tool against hepatitis B virus infection. Some studies have shown that positive results for a hepatitis B virus surface antigen (HBsAg) test may be seen after vaccination. The aim of this study was to compare the incidence of positive HBsAg results after vaccination with two different hepatitis B recombinant vaccines.Materials and Methods: In this clinical trial study, 62 healthy adult volunteers were randomly assigned to receive either the Engerix-B or the Hepavax-Gene hepatitis B recombinant vaccine. Blood samples were drawn 1, 3, and 5 days after vaccination and were tested for HBsAg using two different ELISA kits (Behring and Mega).Results: HBsAg was positive in 5, 3, and 2 participants of the Engerix-B group in the 1st, 3rd, and 5th days after vaccination, respectively, using the Behring ELISA kit; the test was positive in only one subject in the Hepavax-Gene group, on the 5th day after vaccination. No positive result was seen in any groups when the Mega ELISA kit was used to test the specimens. Conclusions: Our results showed transient HBsAg antigenemia after vaccination against hepatitis B. This condition depends on the type of vaccine and the HBsAg diagnostic test.

Yearly Impact:  

View 21495

Download 29323 Citation 0 Refrence 0
Writer: 

SAYAN M. | AKHAN S.C. | BOZDAYI M.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    302
  • End Page: 

    305
Measures: 
  • Citations: 

    0
  • Views: 

    16079
  • Downloads: 

    28403
Keywords: 
Abstract: 

Background and Aims: Previous studies have demonstrated the dominance of genotype D subtype ayw in patients with hepatitis B virus infection in Turkey. The aim of the present study is to report, for the first time, genotype A2 subtype adw2 of hepatitis B virus in a patient who is an inactive hepatitis B carrier in Turkey. Materials and Methods: Hepatitis B virus DNA isolated from the serum sample was amplified by polymerase chain reaction. The polymerase gene segment of the hepatitis B virus was directly sequenced. A distance matrix/UPGMA comparison was used for phylogenetic analysis, and the genotype of the virus was identified accordingly. The subgenotype and subtype of hepatitis B virus were also detected. Results: The genotyping of the patient revealed that the isolated hepatitis B virus was genotype A2/adw2. Discussion: The subtype is inconsistent with the previous data from Turkey; specifically, the identification of the A2/adw2 subtype of the hepatitis B virus in an inactive carrier is the first such case in Turkey. This finding suggests that the transmission of another genotype besides genotype D subtype ayw of the hepatitis B virus is possible in Turkey.

Yearly Impact:  

View 16079

Download 28403 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    306
  • End Page: 

    309
Measures: 
  • Citations: 

    0
  • Views: 

    16031
  • Downloads: 

    22861
Keywords: 
Abstract: 

One of the extra-hepatic manifestations of hepatitis B virus is polyarteritis nodosa (PAN). It may involve medium- and small-sized arteries in any organ. Concurrency of these two diseases may be life threatening and both should be treated. Herein, we report on a patient with severe PAN and high hepatitis B virus load. The patient was an 18-year-old boy with multiple progressive wounds in the skin, referred to our center. The preliminary evaluation showed vasculitis in the skin biopsy compatible with PAN. He was treated with low dose prednisolone and lamivudine for three years. However, his condition got worse and ulcers on his leg became life threatening. The viral load was 17,000,000 copy/mL. The wound developed superimposed resistant bacterial infection. The patient was then treated with two antiviral drugs—lamivudin 100 mg/day plus adefovir 10 mg/day—and high dose cyclophosphamide (750 mg, once a month) and prednisolone (60 mg/day for one month). After six months of treatment, viral load decreased to 100,000 copy/mL and wounds healed. We concluded that high viral load of hepatitis B virus may play an important role in the severity of PAN. We recommend combination therapy with two antiviral agents with high dose of immunosuppressive drugs until both the diseases resolve significantly.

Yearly Impact:  

View 16031

Download 22861 Citation 0 Refrence 0
Writer: 

BURGOS A. | BERMEJO P.E.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    310
  • End Page: 

    310
Measures: 
  • Citations: 

    0
  • Views: 

    16436
  • Downloads: 

    27213
Keywords: 
Abstract: 

Dear Editor, Celiac disease (CD) is an autoimmune disease resulting in inflammatory destruction of small intestinal mucosa after the ingestion of gluten in genetically susceptible individuals. The study of Leonardi and La Rosa (1) tries to establish a possible link between hepatitis B virus (HBV) infection and celiac disease. This is really interesting because only few cases have been described so far in the literature. However, there are two controversial points to be discussed in more detail—the development of CD after HBV infection or after treatment of chronic hepatitis with interferon, and an inadequate response to hepatitis B immunization in patients with CD.

Yearly Impact:  

View 16436

Download 27213 Citation 0 Refrence 0
Writer: 

TURSI A.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    311
  • End Page: 

    312
Measures: 
  • Citations: 

    0
  • Views: 

    16035
  • Downloads: 

    29280
Keywords: 
Abstract: 

Gastroenterology Service, ASL BAT, Andria (BAT), Italy Dear Editor, Celiac disease (CD) is a chronic inflammatory disease of the gut occurring in genetically susceptible individuals after the ingestion of gluten. It is characterized by a flattened mucosa, villous atrophy, and crypt hyperplasia in the small intestine, by the classic malabsorption syndrome (diarrhea, steatorrhea, weight loss), or by seemingly less severe symptoms such as iron deficiency anemia, osteopenic bone disease, amenorrhea, and infertility.

Yearly Impact:  

View 16035

Download 29280 Citation 0 Refrence 0
Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    313
  • End Page: 

    314
Measures: 
  • Citations: 

    0
  • Views: 

    16344
  • Downloads: 

    24902
Keywords: 
Abstract: 

Dear Editor, We read with great interest the article entitled “are hepatitis B virus and celiac disease linked?” by Leonardi, et al, (1) published in Hepatitis Monthly. Celiac disease (CD), also known as gluten-sensitive enteropathy and non-tropical sprue, is a prevalent autoimmune disorder.

Yearly Impact:  

View 16344

Download 24902 Citation 0 Refrence 0
Writer: 

COLLIN P.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    315
  • End Page: 

    316
Measures: 
  • Citations: 

    0
  • Views: 

    16812
  • Downloads: 

    23124
Keywords: 
Abstract: 

Dear Editor, Leonardi and La Rosa (1) investigated the occurrence of celiac disease in patients with hepatitis B by screening their sera with anti-endomysial and anti-tissue transglutaminase antibodies—both of which are sensitive serological tests for celiac disease. The authors found no one with celiac disease in 60 patients who had contracted hepatitis B infection in childhood. As they admitted, the power of the study was too low to make any definitive conclusions.

Yearly Impact:  

View 16812

Download 23124 Citation 0 Refrence 0
Writer: 

FREEMAN H.J.

Journal: 

HEPATITIS MONTHLY

Issue Info: 
  • Year: 

    2010
  • Volume: 

    10
  • Issue: 

    4 (29)
  • Start Page: 

    317
  • End Page: 

    317
Measures: 
  • Citations: 

    0
  • Views: 

    18668
  • Downloads: 

    8750
Keywords: 
Abstract: 

Dear Editor, Evidence suggests a linkage between different environmental agents and the development of celiac disease—an immune-mediated disorder—in those with a specific genetic predisposition (HLA-DQ2, HLA-DQ8) who exposed to gluten—a major storage protein in wheat and other grains. Infections, particularly viral agents, have been hypothesized to induce or exacerbate immune-mediated disorders, possibly through a mechanism of molecular mimicry (1, 2).

Yearly Impact:  

View 18668

Download 8750 Citation 0 Refrence 0

Advertising

مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID
مرکز اطلاعات علمی SID